Tacrolimus Topical and Diltiazem Interaction

Understanding the Tacrolimus Topical and Diltiazem Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Tacrolimus Topical belongs to the Calcineurin Inhibitor (Topical) class and Diltiazem belongs to the Calcium Channel Blocker class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Diltiazem interferes with the way your body processes tacrolimus, which can cause the drug to build up and increase the risk of heart or nerve problems. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Tacrolimus Topical has 25 total documented interactions on file in this dataset, and Diltiazem has 46. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to adjust your dosage and monitor your blood levels frequently to ensure your safety. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Tacrolimus Topical or Diltiazem based on a web page, speak with your prescriber or pharmacist before making any change.